Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins

Clinical Immunology

Volumn 133, Issue 1, 2009, Pages 52-60

  St Amour, Isabelle ^a   Laroche, André ^a   Bazin, Renée ^a,b   Lemieux, Réal ^a,b  

^a Héma Québec ^*  (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Autoreactivity; Cryptic autoantibodies; Intravenous immunoglobulins; Mild denaturation

Indexed keywords

AMYLOID BETA PROTEIN; B CELL ACTIVATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; CONTROLLED STUDY; DENATURATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FRACTIONATION; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; PLASMA; PRIORITY JOURNAL; PURIFICATION; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; B-CELL ACTIVATING FACTOR; ETHANOL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; PROTEIN DENATURATION; SERUM;

EID: 70249123056     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.06.005     Document Type: Article

References (51)

1. Knezevic-Maramica I., and Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion 43 (2003) 1460
2. Lemieux R., Bazin R., and Neron S. Therapeutic intravenous immunoglobulins. Mol. Immunol. 42 (2005) 839
3. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26 (2008) 513
4. Imbach P., Barandun S., and d'Apuzzo V. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet i (1981) 1228
5. Mehta Y.S., and Badakere S.S. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. J. Postgrad. Med. 42 (1996) 46
6. Crow A.R., Song S., Semple J.W., Freedman J., and Lazarus A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br. J. Haematol. 115 (2001) 679
7. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484
8. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E., and Bleeker W.K. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98 (2001) 1095
9. Tremblay T., Aubin E., Lemieux R., and Bazin R. Picogram doses of lipopolysaccharide exacerbate antibody-mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice. Br. J. Haematol. 139 (2007) 297
10. Lazarus A.H. Mechanism of action of IVIG in ITP. Vox Sang. 83 Suppl. 1 (2002) 53
11. Imbach P. Immune thrombocytopenic purpura and intravenous immunoglobulin. Cancer 68 (1991) 1422
12. Lamoureux J., Aubin E., and Lemieux R. Autoimmune complexes in human serum in presence of therapeutic amounts of intravenous immunoglobulins. Blood 101 (2003) 1660
13. Bruhns P., Samuelsson A., Pollard J.W., and Ravetch J.V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18 (2003) 573
14. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670
15. Basta M., Fries L.F., and Frank M.M. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77 (1991) 376
16. Vassilev T.L., Kazatchkine M.D., Van Huyen J.P., Mekrache M., Bonnin E., Mani J.C., Lecroubier C., Korinth D., Baruch D., Schriever F., and Kaveri S.V. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93 (1999) 3624
17. Mouzaki A., Theodoropoulou M., Gianakopoulos I., Vlaha V., Kyrtsonis M.C., and Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 100 (2002) 1774
18. Jarius S., Eichhorn P., Albert M.H., Wagenpfeil S., Wick M., Belohradsky B.H., Hohlfeld R., Jenne D.E., and Voltz R. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood 109 (2007) 4376
19. von Gunten S., Schaub A., Vogel M., Stadler B.M., Miescher S., and Simon H.U. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 (2006) 4255
20. Rossi F., and Kazatchkine M.D. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunol. 143 (1989) 4104
21. Wadhwa M., Meager A., Dilger P., Bird C., Dolman C., Das R.G., and Thorpe R. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology 99 (2000) 113
22. Le Pottier L., Bendaoud B., Dueymes M., Daridon C., Youinou P., Shoenfeld Y., and Pers J.O. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J. Clin. Immunol. 27 (2007) 257
23. Frank M.M., Basta M., and Fries L.F. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin. Immunol. Immunopathol. 62 (1992) S82
24. Dodel R.C., Du Y., Depboylu C., Hampel H., Frolich L., Haag A., Hemmeter U., Paulsen S., Teipel S.J., Brettschneider S., Spottke A., Nolker C., Moller H.J., Wei X., Farlow M., Sommer N., and Oertel W.H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1472
25. Szabo P., Relkin N., and Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun. Rev. 7 (2008) 415
26. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53 (1994) 438
27. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, R.W. Lent, S. Younkin, L. Younkin, R. Schiff, M.E. Weksler, 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol. Aging (in press), doi:10.1016/j.neurobiolaging.2007.12.021.
28. Berneman A., Guilbert B., Eschrich S., and Avrameas S. IgG auto- and polyreactivities of normal human sera. Mol. Immunol. 30 (1993) 1499
29. Seite J.F., Shoenfeld Y., Youinou P., and Hillion S. What is the contents of the magic draft IVIg?. Autoimmun. Rev. 7 (2008) 435
30. Lutz H.U., and Miescher S. Natural antibodies in health and disease: an overview of the first international workshop on natural antibodies in health and disease. Autoimmun. Rev. 7 (2008) 405
31. Cheng H.M., and Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun. Rev. 7 (2008) 431
32. McMahon M.J., and O'Kennedy R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J. Immunol. Methods 241 (2000) 1
33. Dimitrov J.D., Lacroix-Desmazes S., Kaveri S.V., and Vassilev T.L. Insight into the mechanism of the acquired antibody auto-reactivity. Autoimmun. Rev. 7 (2008) 410
34. Bouvet J.P., Stahl D., Rose S., Quan C.P., Kazatchkine M.D., and Kaveri S.V. Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun. 16 (2001) 163
35. Mihaylova N.M., Dimitrov J.D., Djoumerska-Alexieva I.K., and Vassilev T.L. Inflammation-induced enhancement of IgG immunoreactivity. Inflamm. Res. 57 (2008) 1
36. Cohn E.J., Strong L.E., Hughes W.L., Mulford D.J., Ashworth J.N., Melin M., and Taylor H.L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 68 (1946) 459
37. Burnouf T. Modern plasma fractionation. Transfus. Med. Rev. 21 (2007) 101
38. Djoumerska I., Tchorbanov A., Pashov A., and Vassilev T. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand. J. Immunol. 61 (2005) 357
39. Tanaka K., Sawatani E., Dias G.A., Shigueoka E.M., Campos T.C., Nakao H.C., and Arashiro F. High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography. Braz. J. Med. Biol. Res. 33 (2000) 27
40. Lebing W., Remington K.M., Schreiner C., and Paul H.I. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang. 84 (2003) 193
41. Dumont N., Aubin E., Proulx D.P., Lemieux R., and Bazin R. Increased secretion of hyperimmune antibodies following lipopolysaccharide stimulation of CD40-activated human B cells in vitro. Immunology 126 (2009) 588
42. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680
43. Cohen D., Block C., Green M.S., Lowell G., and Ofek I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27 (1989) 162
44. Bussone G., Dib H., Dimitrov J.D., Camoin L., Broussard C., Tamas N., Guillevin L., Kaveri S.V., and Mouthon L. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. Proteomics 9 (2009) 2253
45. Li Q., Gordon M., Cao C., Ugen K.E., and Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci. 8 (2007) 22
46. Dimitrov J.D., Lacroix-Desmazes S., Kaveri S.V., and Vassilev T.L. Transition towards antigen-binding promiscuity of a monospecific antibody. Mol. Immunol. 44 (2007) 1854
47. Watanabe M., Uchida K., Nakagaki K., Kanazawa H., Trapnell B.C., Hoshino Y., Kagamu H., Yoshizawa H., Keicho N., Goto H., and Nakata K. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581 (2007) 2017
48. Bruley-Rosset M., Mouthon L., Chanseaud Y., Dhainaut F., Lirochon J., and Bourel D. Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases. Lab. Invest. 83 (2003) 1013
49. Lamoureux J., Aubin E., and Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg?. Int. Immunol. 16 (2004) 929
50. Svenson M., Hansen M.B., Ross C., Diamant M., Rieneck K., Nielsen H., and Bendtzen K. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91 (1998) 2054
51. Nydegger U.E. Safety and side effects of i.v. immunoglobulin therapy. Clin. Exp. Rheumatol. 14 Suppl. 15 (1996) S53